Cyclopharm Limited (AU:CYC)
ASX:CYC
Want to see AU:CYC full AI Analyst Report?
CYC Stock Chart & Stats
AU$0.98
-AU$0.04(-1.82%)
At close: 4:00 PM EST
AU$0.98
-AU$0.04(-1.82%)
Day’s Range― - ―
52-Week RangeAU$0.56 - AU$1.29
Previous CloseN/A
Volume20.15K
Average Volume (3M)97.64K
Market Cap
AU$85.09M
Enterprise ValueAU$97.80M
Total Cash (Recent Filing)AU$6.63M
Total Debt (Recent Filing)AU$14.92M
Price to Earnings (P/E)―
Beta0.54
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding126,065,790
10 Day Avg. Volume155,345
30 Day Avg. Volume97,642
Financial Highlights & Ratios
PEG Ratio-0.27
Price to Book (P/B)3.98
Price to Sales (P/S)3.34
P/FCF Ratio-5.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.00Price Target Upside2.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.05
Revenue Forecast (FY)AU$47.80M
Bulls Say, Bears Say
Bulls Say
Recurring Consumable RevenueCyclopharm’s business model generates repeatable, procedure-tied revenue from Technegas consumables and associated service, creating a durable, usage-driven income stream. Recurring disposables aligned with installed equipment support predictable unit economics and long-term revenue per customer.
Steady Top-line GrowthConsistent revenue growth through 2025 signals improving commercial traction and adoption of Technegas across markets. Sustained top-line momentum supports scale benefits and validates product-market fit, important for durability if the company can translate volumes to improved margins over time.
Meaningful Equity BufferA material equity base (~A$27m in 2025) provides a tangible financial cushion to absorb operating losses and fund near-term operations. That equity buffer increases resilience versus immediate insolvency risk and gives management time to pursue commercialization or margin-improvement initiatives.
Bears Say
Deep Cash BurnSustained large negative operating and free cash flows (~-A$17m to -A$19m in 2025) indicate the business consumes substantial capital to run and grow. Ongoing cash burn creates persistent funding needs, increases dilution or debt reliance, and limits strategic flexibility absent durable margin improvement.
Negative Gross ProfitA negative gross profit in 2025 signals structural margin pressure: product, manufacturing, pricing or mix issues that cause costs to exceed revenue. Unless resolved, this undermines scalability because higher volumes will not deliver operating leverage until unit economics are restored.
Rising LeverageMaterial increase in debt alongside declining equity tightens the balance sheet and raises refinancing and interest-rate risk. Higher leverage constrains capital allocation, elevates fixed obligations, and reduces resilience to operational setbacks, pressuring long-term viability if profitability remains weak.
Cyclopharm Limited News
CYC FAQ
What was Cyclopharm Limited’s price range in the past 12 months?
Cyclopharm Limited lowest share price was AU$0.56 and its highest was AU$1.29 in the past 12 months.
What is Cyclopharm Limited’s market cap?
Cyclopharm Limited’s market cap is AU$85.09M.
When is Cyclopharm Limited’s upcoming earnings report date?
Cyclopharm Limited’s upcoming earnings report date is Aug 17, 2026 which is in 73 days.
How were Cyclopharm Limited’s earnings last quarter?
Cyclopharm Limited released its earnings results on Feb 25, 2026. The company reported -AU$0.086 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.086.
Is Cyclopharm Limited overvalued?
According to Wall Street analysts Cyclopharm Limited’s price is currently Undervalued.
Does Cyclopharm Limited pay dividends?
Cyclopharm Limited pays a Semiannually dividend of AU$0.008 which represents an annual dividend yield of N/A. See more information on Cyclopharm Limited dividends here
What is Cyclopharm Limited’s EPS estimate?
Cyclopharm Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cyclopharm Limited have?
Cyclopharm Limited has 126,065,790 shares outstanding.
What happened to Cyclopharm Limited’s price movement after its last earnings report?
Cyclopharm Limited reported an EPS of -AU$0.086 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.765%.
Which hedge fund is a major shareholder of Cyclopharm Limited?
Currently, no hedge funds are holding shares in AU:CYC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cyclopharm Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$1.00 (2.04% Upside)
AU$1.00 (2.04% Upside)
Blogger Sentiment
Bullish
AU:CYC Sentiment 89%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$75.0K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.35%
12-Months-Change
Fundamentals
Return on Equity
-54.48%
Trailing 12-Months
Asset Growth
-25.80%
Trailing 12-Months
Company Description
Cyclopharm Limited
Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally. It operates through Technegas and Molecular Imaging segments. The Technegas segment offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism. This segment also distributes third party products to the diagnostic imaging sector. The Molecular Imaging segment provides radiopharmaceuticals that are used by physicians in the detection of cancer, neurological disorders, and cardiac diseases. The company serves nuclear medicine departments. Cyclopharm Limited was founded in 1986 and is headquartered in Kingsgrove, Australia.
CYC Stock 12 Month Forecast
Average Price Target
AU$1.00
▲(2.04% Upside)
Technical Analysis
Compumedics Limited
―
Impedimed Limited
―
Aroa Biosurgery Ltd
―
EMvision Medical Devices Ltd.
―
4DMedical Ltd
―
Options Prices
Currently, No data available
---